132 related articles for article (PubMed ID: 8744561)
1. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.
Vaughn DW; Hoke CH; Yoksan S; LaChance R; Innis BL; Rice RM; Bhamarapravati N
Vaccine; 1996 Mar; 14(4):329-36. PubMed ID: 8744561
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
3. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
Hoke CH; Malinoski FJ; Eckels KH; Scott RM; Dubois DR; Summers PL; Simms T; Burrous J; Hasty SE; Bancroft WH
Am J Trop Med Hyg; 1990 Aug; 43(2):219-26. PubMed ID: 2389825
[TBL] [Abstract][Full Text] [Related]
4. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N
Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219
[TBL] [Abstract][Full Text] [Related]
6. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.
Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Eckels KH; Dubois DR; Summers PL; Hoke CH
J Infect Dis; 1994 Dec; 170(6):1448-55. PubMed ID: 7995984
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.
Kanesa-Thasan N; Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Coster TS; Kim-Ahn GJ; Dubois DR; Putnak JR; King A; Summers PL; Innis BL; Eckels KH; Hoke CH
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):17-23. PubMed ID: 14740951
[TBL] [Abstract][Full Text] [Related]
8. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.
Bancroft WH; Top FH; Eckels KH; Anderson JH; McCown JM; Russell PK
Infect Immun; 1981 Feb; 31(2):698-703. PubMed ID: 7216469
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.
Bhamarapravati N; Yoksan S; Chayaniyayothin T; Angsubphakorn S; Bunyaratvej A
Bull World Health Organ; 1987; 65(2):189-95. PubMed ID: 3496985
[TBL] [Abstract][Full Text] [Related]
10. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
11. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.
Bancroft WH; Scott RM; Eckels KH; Hoke CH; Simms TE; Jesrani KD; Summers PL; Dubois DR; Tsoulos D; Russell PK
J Infect Dis; 1984 Jun; 149(6):1005-10. PubMed ID: 6376649
[TBL] [Abstract][Full Text] [Related]
12. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
13. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952
[TBL] [Abstract][Full Text] [Related]
18. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
19. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
